Eli Lilly And Co Beats Earnings Estimates, Procter & Gamble Co In Line

Eli Lilly And Co Beats Earnings Estimates, Procter & Gamble Co In Line
<a href="https://pixabay.com/users/geralt/">geralt</a> / Pixabay

Eli Lilly and Procter & Gamble released the earnings results from their most recently completed quarters before opening bell this morning.

Eli Lilly posted adjusted earnings of 87 cents per share on revenue of $4.64 billion for the first quarter. Analysts were expecting earnings of 76 cents per share on $4.62 billion in revenue. In the same quarter a year ago, the drug maker reported adjusted earnings of 74 cents on $4.68 billion in revenue.

Canyon Distressed Opportunity Fund likes the backdrop for credit

CanyonThe Canyon Distressed Opportunity Fund III held its final closing on Jan. 1 with total commitments of $1.46 billion, calling half of its capital commitments so far. Canyon has about $26 billion in assets under management now. Q4 2020 hedge fund letters, conferences and more Positive backdrop for credit funds In their fourth-quarter letter to Read More

For its third fiscal quarter, Procter & Gamble reported adjusted earnings of 92 cents per share, which was in line with the consensus estimate. The consumer products company reported a sales decline of 8% to $18.1 billion for the quarter. Analysts had been expecting sales of $18.4 billion.

Key metrics from Eli Lilly’s earnings report

Eli Lilly’s net earnings were 50 cents per share, compared to 68 cents per share a year ago. Eli Lilly said the 1% decline was due to negative impacts from foreign exchange rates and continuing negative impacts from the patent expirations on osteoporosis drug Evista and Cymbalta.

Sales of insulin drug Humalog continued to lead the way, accounting for $684 million of Eli Lilly’s total revenue, a 5% increase. Sales of anti-psychotic drug Zyprexa declined 22% year over year to $219.5 million, while anti-depressant Cymbalta  sales fell 40% to $287 million. Eli Lilly’s animal health segment saw sales increase 42% year over year to $749.8 million, while sales of ADHD drug Strattera increased 13% to $173.7 million.

Eli Lilly maintained its guidance of adjusted earnings of between $3.10 and $3.20 per share but adjusted net earnings guidance to between $2.21 and $2.31 per share.

Key metrics from Procter & Gamble’s earnings report

Procter & Gamble’s GAAP earnings were 75 cents per share, compared to 90 cents last year. The company’s Beauty, Hair and Personal Care segment saw a 3% decline in organic sales because lower volumes more than offset positive pricing impacts. In the Grooming segment, organic sales rose 9% due to higher prices.

The company’s Health Care segment recorded a 6% increase in organic sales due to a favorable geographic mix and pricing. Procter & Gamble’s Fabric Care and Home Care division saw flat organic sales as lower Fabric Care volume offset higher P&G Professional volume and positive impacts from product and geographic mix.

The Baby, Feminine and Family Care division recorded a 2% increase in sales due to positive benefits from product mix and pricing.

Procter & Gamble said it expects organic sales growth for the fiscal year to be in the low single digits and core earnings to increase in the double digits.

No posts to display